Analysts Offer Insights on Healthcare Companies: Impedimed Limited (OtherIPDQF) and Mach7 Technologies (OtherTDMMF)

Business Insider

06-05-2025

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Impedimed Limited (IPDQF – Research Report) and Mach7 Technologies (TDMMF – Research Report) with bullish sentiments.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Impedimed Limited (IPDQF)
In a report released today, Scott Power from Morgans maintained a Buy rating on Impedimed Limited, with a price target of A$0.15. The company's shares closed last Thursday at $0.04.
Power has an average return of 14.0% when recommending Impedimed Limited.
According to TipRanks.com, Power is ranked #8478 out of 9504 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Impedimed Limited with a $0.08 average price target, an 113.9% upside from current levels. In a report issued on April 30, Canaccord Genuity also maintained a Buy rating on the stock with a A$0.09 price target.
Morgans analyst Iain Wilkie maintained a Buy rating on Mach7 Technologies today and set a price target of A$1.37. The company's shares closed last Tuesday at $0.24, equals to its 52-week low of $0.24.
According to TipRanks.com, Wilkie is ranked #8787 out of 9504 analysts.
Mach7 Technologies has an analyst consensus of Strong Buy, with a price target consensus of $0.65, representing a 170.8% upside. In a report issued on April 30, Wilsons also maintained a Buy rating on the stock with a A$0.85 price target.